Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

101. Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors

Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors 28922087 2017 12 11 2017 12 15 1527-7755 35 34 2017 Dec 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. 3837-3843 10.1200/JCO.2017.72.4211 Purpose The use of anthracycline chemotherapy is associated with heart failure (HF) among survivors (...) of non-Hodgkin lymphoma (NHL). We aimed to understand the contribution of preexisting cardiovascular risk factors to HF risk among NHL survivors. Methods Using Danish registries, we identified adults diagnosed with aggressive NHL from 2000 to 2010 and sex- and age-matched general-population controls. We assessed HF from 9 months after diagnosis through 2012. We used Cox regression analysis to assess differences in risk for HF between survivors and general population controls. Among survivors only

EvidenceUpdates2017

102. Exercise performance, haemodynamics, and respiratory pattern do not identify heart failure patients who end exercise with dyspnoea from those with fatigue

Exercise performance, haemodynamics, and respiratory pattern do not identify heart failure patients who end exercise with dyspnoea from those with fatigue Exercise performance, haemodynamics, and respiratory pattern do not identify heart failure patients who end exercise with dyspnoea from those with fatigue † Marco Morosin 1,2 , Stefania Farina 1 , Carlo Vignati 1 , Emanuele Spadafora 1 , Susanna Sciomer 3 , Elisabetta Salvioni 1 , Gianfranco Sinagra 2 and Piergiuseppe Agostoni 1,4 * 1 Centro (...) Cardiologico Monzino, IRCCS, Milan, Italy; 2 Cardiovascular Department ‘Ospedali Riuniti’ Trieste and Postgraduate School Cardiovascular Sciences, University of Trieste,Trieste, Italy; 3 Department of Cardiovascular, Respiratory, Geriatric, Nephrology and Anesthesiology Sciences, Sapienza University of Rome, Rome, Italy; and 4 Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milan, Milan, Italy Abstract Aims The two main symptoms referred by chronic heart failure

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

103. Peripheral muscle training with resistance exercise bands in patients with chronic heart failure. Long‐term effects on walking distance and quality of life; a pilot study

Peripheral muscle training with resistance exercise bands in patients with chronic heart failure. Long‐term effects on walking distance and quality of life; a pilot study Peripheral muscle training with resistance exercise bandsinpatientswithchronicheartfailure.Long-term effects on walking distance and quality of life; a pilot study Charlotta Lans 1,2 * , Åsa Cider 3,4 , Eva Nylander 2,5 and Lars Brudin 2,6 1 Department of Physiotherapy, Kalmar County Hospital, Kalmar, Sweden; 2 Department (...) This study aimed to describe a method of peripheral muscle training with resistance bands in patients with chronic heart failure (CHF) and to evaluate its effects on the 6 min walk test and quality of life up to 12 months using a home- based programme. Methods and results Twenty-two patients with stable CHF (19 men and 3 women), mean age 63.2 years (SD 8.1), New York Heart Association class II–III were randomized to individual home-based training (HT group), or home-based training with a group-basedstart

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

104. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals.

Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. BACKGROUND: Large-scale and contemporary population-based studies of heart failure incidence are needed to inform resource planning and research prioritisation but current evidence is scarce. We aimed to assess temporal trends in incidence and prevalence of heart failure in a large general population cohort from the UK, between 2002 and 2014. METHODS: For this population-based study, we (...) practice for at least 12 months. For patients with incident heart failure, we extracted the most recent measurement of baseline characteristics (within 2 years of diagnosis) from electronic health records, as well as information about comorbidities, socioeconomic status, ethnicity, and region. We calculated standardised rates by applying direct age and sex standardisation to the 2013 European Standard Population, and we inferred crude rates by applying year-specific, age-specific, and sex-specific incidence to UK

Lancet2017

105. Magnetic resonance imaging in heart failure, including coronary imaging: numbers, facts, and challenges

Magnetic resonance imaging in heart failure, including coronary imaging: numbers, facts, and challenges Magnetic resonance imaging in heart failure, including coronary imaging: numbers, facts, and challenges Lisa Adams 1 , Michel Noutsias 2 , Boris Bigalke 3 and Marcus R. Makowski 1,4 1 Klinik für Radiologie, Charité – Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, D -10117, Berlin, Germany; 2 Department of Internal Medicine I, Division of Cardiology, Pneumology, Angiology (...) and Intensive Medical Care, University Hospital Jena, Friedrich Schiller University Jena, Jena, Germany; 3 Klinik für Kardiologie, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany; 4 Division of Imaging Sciences and Biomedical Engineering, King’s College London, London, UK Abstract Coronary artery disease (CAD) is a major risk factor for the incidence and progression of heart failure (HF). HF is characterized by a substantial morbidity and mortality and its lifetime risk

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

106. Muscle wasting and sarcopenia in heart failure and beyond: update 2017

Muscle wasting and sarcopenia in heart failure and beyond: update 2017 Muscle wasting and sarcopenia in heart failure and beyond: update 2017 Jochen Springer 1 * , Joshua-I. Springer 1 and Stefan D. Anker 2 1 Department of Cardiology and Pneumology, University Medical Center Göttingen (UMG), Göttingen, Germany; 2 Division of Cardiology and Metabolism—Heart Failure, Cachexia and Sarcopenia, Department of Cardiology (CVK); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT); Deutsches (...) including chronic heart failure (CHF) in the elderly pop- ulation with numbers affected reaching approximately 2% of the population. 1,2 CHF prevalence increases strongly with age and its rates double approximately every 10 years in male and every 7 years in female patients after 55 years of age; hence, the majority of CHF patients are elderly to very old and the numbers of affected people are expected to rise with the increased overall life expectancy, particularly in Asia. 3–6 Overall, CHF leads to

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

107. Publishing in a heart failure journal—where lies the scientific interest?

Publishing in a heart failure journal—where lies the scientific interest? Publishing in a heart failure journal—where lies the scienti?c interest? Amir Emami, Nicole Ebner and Stephan von Haehling Department of Cardiology and Pneumology, University of Göttingen Medical Center, Robert-Koch-Strasse 40, D-37075, Göttingen, Germany Whenyoucreateanewjournal,likeESCHeartFailure,people giveyouaratherlotoftimefordevelopmentofstyleandper- formance.Nowadays,itregularlytakes4–6yearstogetrecog- nized (...) in PubMed and then another 1–2 years to obtain an impact factor. That is, when all is going reasonably well. When you take over an established journal, like the European Journal of Heart Failure, people expect fast success or at least visible change. With regard to the look and feel of a journal, editorial style, and communication as well as editorial of?ce performance, it is indeed possible for a new editor-in-chief to give a journal a new style fairly quickly. However, performance markers like

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

108. Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure

Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure 29128869 2018 11 13 2380-6591 3 1 2018 Jan 01 JAMA cardiology JAMA Cardiol Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. 44-53 10.1001/jamacardio.2017.4265 Public reporting of hospitals' 30-day risk-standardized readmission rates following heart failure hospitalization (...) and the financial penalization of hospitals with higher rates have been associated with a reduction in 30-day readmissions but have raised concerns regarding the potential for unintended consequences. To examine the association of the Hospital Readmissions Reduction Program (HRRP) with readmission and mortality outcomes among patients hospitalized with heart failure within a prospective clinical registry that allows for detailed risk adjustment. Interrupted time-series and survival analyses of index heart failure

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

109. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial 29020355 2017 10 11 2017 10 11 1522-9645 2017 Aug 28 European heart journal Eur. Heart J. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. 10.1093/eurheartj/ehx511 Empagliflozin reduced the risk of cardiovascular (...) (CV) death and heart failure (HF) hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in the EMPA-REG OUTCOME® trial. We investigated whether the benefit of empagliflozin was observed across the spectrum of HF risk. Seven thousand and twenty patients with T2D (HbA1c 7-10% and eGFR > 30 mL/min/1.73 m2) were treated with empagliflozin 10 or 25 mg, or placebo once daily and followed for median 3.1 years. In patients without HF at baseline (89.9%), we derived the 5

EvidenceUpdates2017

110. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials

Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials 29040525 2017 10 17 2017 10 17 1522-9645 2017 Oct 10 European heart journal Eur. Heart J. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. 10.1093/eurheartj/ehx564 Recent guidelines recommend that patients with heart failure (...) and left ventricular ejection fraction (LVEF) 40-49% should be managed similar to LVEF ≥ 50%. We investigated the effect of beta-blockers according to LVEF in double-blind, randomized, placebo-controlled trials. Individual patient data meta-analysis of 11 trials, stratified by baseline LVEF and heart rhythm (Clinicaltrials.gov: NCT0083244; PROSPERO: CRD42014010012). Primary outcomes were all-cause mortality and cardiovascular death over 1.3 years median follow-up, with an intention-to-treat

EvidenceUpdates2017

111. Home-based telerehabilitation in older patients with chronic obstructive pulmonary disease and heart failure: a randomised controlled trial

Home-based telerehabilitation in older patients with chronic obstructive pulmonary disease and heart failure: a randomised controlled trial 28985325 2017 10 06 2017 10 06 1468-2834 2017 Aug 30 Age and ageing Age Ageing Home-based telerehabilitation in older patients with chronic obstructive pulmonary disease and heart failure: a randomised controlled trial. 1-7 10.1093/ageing/afx146 chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) frequently coexist in older people (...) , reducing patients' quality of life (QoL) and increasing morbidity and mortality. we studied the feasibility and efficacy of an integrated telerehabilitation home-based programme (Telereab-HBP), 4 months long, in patients with combined COPD and CHF. The primary outcome was exercise tolerance evaluated at the 6-min walk test (6MWT). Secondary outcomes were time-to-event (hospitalisation and death), dyspnoea (MRC), physical activity profile (PASE), disability (Barthel) and QoL (MLHFQ and CAT). randomised

EvidenceUpdates2017

112. Palliative Care in Heart Failure: Rationale, Evidence, and Future Priorities

Palliative Care in Heart Failure: Rationale, Evidence, and Future Priorities 28982506 2017 10 06 2017 10 16 2017 10 20 1558-3597 70 15 2017 Oct 10 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Palliative Care in Heart Failure: Rationale, Evidence, and Future Priorities. 1919-1930 S0735-1097(17)39343-9 10.1016/j.jacc.2017.08.036 Patients with heart failure (HF) and their families experience stress and suffering from a variety of sources over the course of the HF experience (...) . Palliative care is an interdisciplinary service and an overall approach to care that improves quality of life and alleviates suffering for those living with serious illness, regardless of prognosis. In this review, we synthesize the evidence from randomized clinical trials of palliative care interventions in HF. While the evidence base for palliative care in HF is promising, it is still in its infancy and requires additional high-quality, methodologically sound studies to clearly elucidate the role

EvidenceUpdates2017

113. Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials

Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials 29094152 2018 11 13 2380-6591 2 12 2017 Dec 01 JAMA cardiology JAMA Cardiol Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction (...) : A Secondary Analysis of 2 Randomized Clinical Trials. 1315-1321 10.1001/jamacardio.2017.3983 While there is increasing emphasis on incorporating patient-reported outcome measures in routine care for patients with heart failure (HF), how best to interpret longitudinally collected patient-reported outcome measures is unknown. To examine the strength of association between prior, current, or a change in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores with death and hospitalization in patients with HF

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

114. Chronic obstructive pulmonary disease and β‐blocker treatment in Asian patients with heart failure

Chronic obstructive pulmonary disease and β‐blocker treatment in Asian patients with heart failure 29055972 2018 11 13 2055-5822 5 2 2018 04 ESC heart failure ESC Heart Fail Chronic obstructive pulmonary disease and β-blocker treatment in Asian patients with heart failure. 297-305 10.1002/ehf2.12228 Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are increasingly frequent in Asia and commonly coexist in patients. However, the prevalence of COPD among Asian patients (...) with HF and its impact on HF treatment are unclear. We compared clinical characteristics and treatment approaches between patients with or without a history of COPD, before and after 1:2 propensity matching (for age, sex, geographical region, income level, and ethnic group) in 5232 prospectively recruited patients with HF and reduced ejection fraction (HFrEF, <40%) from 11 Asian regions (Northeast Asia: South Korea, Japan, Taiwan, Hong Kong, and China; South Asia: India; Southeast Asia: Thailand

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

115. Use of sacubitril/valsartan in acute decompensated heart failure: a case report

Use of sacubitril/valsartan in acute decompensated heart failure: a case report 29035000 2018 10 25 2018 11 13 2055-5822 5 1 2018 02 ESC heart failure ESC Heart Fail Use of sacubitril/valsartan in acute decompensated heart failure: a case report. 184-188 10.1002/ehf2.12219 Refractory heart failure typically requires costly long-term, continuous intravenous inodilator infusions while patients await mechanical circulatory support or cardiac transplantation. The combined angiotensin (...) receptor blocker-neprilysin inhibitor, sacubitril/valsartan, is a novel therapy that can increase levels of endogenous vasoactive peptides. This therapy has been recommended as an alternative agent in patients with chronic heart failure with reduced ejection fraction and New York Heart Association class II-III symptoms. Here, we report a case of a patient with refractory stage D heart failure with reduced ejection fraction who was successfully weaned off continuous intravenous inodilator support using sacubitril

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

116. Global longitudinal strain corrected by RR interval is a superior predictor of all‐cause mortality in patients with systolic heart failure and atrial fibrillation

Global longitudinal strain corrected by RR interval is a superior predictor of all‐cause mortality in patients with systolic heart failure and atrial fibrillation 29024533 2018 11 13 2055-5822 5 2 2018 04 ESC heart failure ESC Heart Fail Global longitudinal strain corrected by RR interval is a superior predictor of all-cause mortality in patients with systolic heart failure and atrial fibrillation. 311-318 10.1002/ehf2.12220 Quantification of systolic function in patients (...) with atrial fibrillation (AF) is challenging. A novel approach, based on RR interval correction, to counteract the varying heart cycle lengths in AF has recently been proposed. Whether this method is superior in patients with systolic heart failure (HFrEF) with AF remains unknown. This study investigates the prognostic value of RR interval-corrected peak global longitudinal strain {GLSc = GLS/[RR^(1/2)]} in relation to all-cause mortality in HFrEF patients displaying AF during echocardiographic examination

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

117. Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR‐AHF

Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR‐AHF 28980452 2018 07 16 2018 11 13 2055-5822 4 4 2017 11 ESC heart failure ESC Heart Fail Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR-AHF. 479-486 10.1002/ehf2.12226 Although loop diuretics are the most commonly used drugs in acute heart failure (AHF) treatment, their short-term and long-term effects are relatively unknown (...) with a diagnosis of acute heart failure, BNP ≥ 100 pg/mL, and specific chest X-ray signs. Randomization criteria have been established at a 1:1 ratio using a computer-generated scheme of either twice-daily bolus injection or continuous infusion for a time period ranging from 72 to 120 h. The initial dose will be 80 mg/day of intravenous furosemide and, in the case of poor response, will be doubled using an escalation algorithm. A high diuretic dose is defined as a furosemide daily amount >120 mg/day

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

118. Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department: A Cohort Study.

Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department: A Cohort Study. Background: Physicians in the emergency department (ED) need additional tools to stratify patients with acute heart failure (AHF) according to risk. Objective: To predict mortality using data that are readily available at ED admission. Design: Prospective cohort study. Setting: 34 Spanish EDs. Participants: The derivation cohort included 4867 consecutive ED patients admitted during

Annals of Internal Medicine2017

119. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction

Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction 28967709 2018 11 13 2055-5822 5 2 2018 04 ESC heart failure ESC Heart Fail Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. 262-270 10.1002/ehf2.12222 Heart failure with preserved ejection fraction (HFpEF) has several pathophysiological aspects, including stiffness and/or congestion of multiple organs. Poor prognosis is expected in heart failure (...) . © 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. Yoshihisa Akiomi A Department of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan. Sato Yu Y Department of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan. Yokokawa Tetsuro T Department of Cardiovascular Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

120. The association between high‐dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure

The association between high‐dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure 28967699 2018 10 25 2018 11 13 2055-5822 5 1 2018 02 ESC heart failure ESC Heart Fail The association between high-dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure. 87-94 10.1002/ehf2.12221 Few studies have reported the impact of high-dose loop diuretics at discharge on prognosis in Japanese patients with heart failure (HF (...) ). Our purpose was to assess the relationship between the dose of loop diuretics at discharge and cardiovascular mortality in patients with HF. We enrolled decompensated HF patients who were admitted to our hospital between March 2010 and March 2015, and compared HF patients who received high-dose loop diuretics at discharge (HD group) with low-dose loop diuretics at discharge (LD group) with regard to risk of cardiovascular mortality, and all-cause mortality. High-dose loop diuretic was defined

ESC heart failure2017 Full Text: Link to full Text with Trip Pro